Literature DB >> 31654093

Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients.

Sofia Vaz1, Boris Hadaschik2, Michael Gabriel3, Ken Herrmann4, Matthias Eiber5, Durval Costa6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31654093     DOI： 10.1007/s00259-019-04529-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  18 in total

1.  Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.

Authors:  S S Chang; V E Reuter; W D Heston; B Hutchinson; L S Grauer; P B Gaudin
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

2.  Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.

Authors:  Michael J Evans; Peter M Smith-Jones; John Wongvipat; Vincent Navarro; Sae Kim; Neil H Bander; Steven M Larson; Charles L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-23       Impact factor: 11.205

3.  Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.

Authors:  Isabel Rauscher; Charlotte Düwel; Bernhard Haller; Christoph Rischpler; Matthias M Heck; Jürgen E Gschwend; Markus Schwaiger; Tobias Maurer; Matthias Eiber
Journal:  Eur Urol       Date:  2018-01-19       Impact factor: 20.096

4.  Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.

Authors:  Jose D Murga; Sameer M Moorji; Amy Q Han; Wells W Magargal; Vincent A DiPippo; William C Olson
Journal:  Prostate       Date:  2014-10-18       Impact factor: 4.104

Review 5.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.

Authors:  Arundhati Ghosh; Warren D W Heston
Journal:  J Cell Biochem       Date:  2004-02-15       Impact factor: 4.429

6.  Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.

Authors:  Benedikt Kranzbühler; Souzan Salemi; Christoph A Umbricht; Cristina Müller; Irene A Burger; Tullio Sulser; Daniel Eberli
Journal:  Prostate       Date:  2018-04-06       Impact factor: 4.104

7.  Bone Flare to Androgen Deprivation Therapy in Metastatic, Hormone-Sensitive Prostate Cancer on 68Ga-Prostate-Specific Membrane Antigen PET/CT.

Authors:  Helle D Zacho; Lars J Petersen
Journal:  Clin Nucl Med       Date:  2018-11       Impact factor: 7.794

8.  Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?

Authors:  Conrad Leitsmann; Paul Thelen; Marianne Schmid; Johannes Meller; Carsten-Oliver Sahlmann; Birgit Meller; Lutz Trojan; Arne Strauss
Journal:  Int Braz J Urol       Date:  2019 May-Jun       Impact factor: 1.541

9.  Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells.

Authors:  Tiancheng Liu; Lisa Y Wu; Melody D Fulton; Jacqueline M Johnson; Clifford E Berkman
Journal:  Int J Oncol       Date:  2012-10-04       Impact factor: 5.650

10.  Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy.

Authors:  B Meller; F Bremmer; C O Sahlmann; S Hijazi; C Bouter; L Trojan; J Meller; P Thelen
Journal:  EJNMMI Res       Date:  2015-11-17       Impact factor: 3.138
View more
  26 in total

1.  PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?

Authors:  Laura Evangelista; Pierpaolo Alongi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-13       Impact factor: 9.236

Review 2.  [Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists-when and which tracer?]

Authors:  Christoph Berliner; Claudia Kesch; Wolfgang P Fendler; Matthias Eiber; Tobias Maurer
Journal:  Urologe A       Date:  2022-02-09       Impact factor: 0.639

3.  Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment.

Authors:  Tugba Akin Telli; Salih Ozguven; Ozkan Alan; Nuh Filizoglu; Mehmet Akif Ozturk; Nisanur Sariyar; Selver Isik; Rukiye Arikan; Nazim Can Demircan; Tugba Basoglu; Ilknur Alsan Cetin; Tunc Ones; Ozlem Ercelep; Faysal Dane; Perran Fulden Yumuk
Journal:  Ann Nucl Med       Date:  2022-08-23       Impact factor: 2.258

Review 4.  Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  PET Clin       Date:  2022-05-31

Review 5.  Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells.

Authors:  Wojciech Szlasa; Natalia Janicka; Natalia Sauer; Olga Michel; Bernadetta Nowak; Jolanta Saczko; Julita Kulbacka
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

6.  Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.

Authors:  John R Bright; Rosina T Lis; Anson T Ku; Nicholas T Terrigino; Nichelle C Whitlock; Shana Y Trostel; Nicole V Carrabba; Stephanie A Harmon; Baris Turkbey; Scott Wilkinson; Adam G Sowalsky
Journal:  J Urol       Date:  2022-03-01       Impact factor: 7.600

Review 7.  Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.

Authors:  Gaëtan Devos; Wout Devlies; Gert De Meerleer; Marcella Baldewijns; Thomas Gevaert; Lisa Moris; Daimantas Milonas; Hendrik Van Poppel; Charlien Berghen; Wouter Everaerts; Frank Claessens; Steven Joniau
Journal:  Nat Rev Urol       Date:  2021-09-15       Impact factor: 14.432

8.  Competitive Advantage of PSMA Theranostics in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  Radiology       Date:  2021-03-30       Impact factor: 29.146

9.  18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study.

Authors:  Harun Ilhan; Markus Kroenke; Alexander Wurzer; Marcus Unterrainer; Matthias Heck; Claus Belka; Karina Knorr; Thomas Langbein; Isabel Rauscher; Nina-Sophie Schmidt-Hegemann; Kilian Schiller; Peter Bartenstein; Hans-Jürgen Wester; Matthias Eiber
Journal:  J Nucl Med       Date:  2022-03-10       Impact factor: 11.082

Review 10.  More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.

Authors:  Anniina Hyväkkä; Verneri Virtanen; Jukka Kemppainen; Tove J Grönroos; Heikki Minn; Maria Sundvall
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.